Abiola Muhammad ADEOSUN, Aduragbenro D A ADEDAPO, Waheed Adeola ADEDEJİ

Adverse drug reactions report among hospitalized patients with hypertension in a Nigerian Tertiary Healthcare Centre: a retrospective study

Adverse drug reactions (ADRs) are serious clinical problem with growing global concern. This study focused on incidence and outcome of ADRs among inpatients with hypertension in Nigeria. This was a cross-sectional study on incidence of adverse drug reactions among in-patients with hypertension conducted in the University College Hospital (UCH), Ibadan, Nigeria, within June 2012 to May 2013. Of 196 patients, 105 (53.6%) were male, and 91 (46.4%) were female. Prevalence of ADRs was 53 (27.04%), of these, 28 (52.8%) were male, and 25 (47.2%) were female. Adverse drug reaction was cause of admission in 2 (1.02%) patients. Prevalence of ADRs during hospitalization was 51 (26.02%) patients. Patients with adverse drug event spent approximately additional 5 days more in bed compared to those without adverse drug reactions (p = 0.028). ADRs experienced by the patients were managed by withdrawing the suspected drug(s). In conclusion, ADR was cause of admission in 1% of in-patients with hypertension, while ADRs was recorded in 53 (27.04%) hospitalised patients with hypertension. Patients that experienced ADR spent additional approximately five days in hospital compared to those without adverse drug effect during hospitalization

PDF

___

1. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009;4(2):e4439.

2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-9.

3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998;279(15):1200-5.

4. Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tegeder I, Schneider HT, Hahn EG, Levy M, Brune K, Geisslinger . Incidence and costs of adverse drug reactions during hospitalisation. Drug Safety. 2000;22(2):161-8.

5. Rodriguez-Monguio R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics. 2003;21(9):623- 50.

6. James PA, Oparil S, Carter BL, Cushman WC, DennisonHimmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.

7. Yusuf KB, Balogun BO. Pattern of drug utilization among hypertensives in a Nigerian teaching hospital. Pharmacoepidemiol Drug Saf. 2005;14(1): 69-74

8. Ukwe CV, Ubaka MC. Antihypertensive drug prescribing in a tertiary hospital in eastern Nigeria. Trop J Pharm Res. 2012;11(2):297-305.

9. Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E. Janecek E, Domecq C, Greenblatt DJ. ADR probability scale. Clin Pharmacol Ther. 1981;30(2):239-45.

10. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229-32.

11. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee WHO Technical Report Series 854. Geneva: World Health Organization; 1995.

12. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301-6.

13. Ambrosio AF, Soares-da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochemical Res. 2002;27(1-2):121-30.

14. Kasarskis EJ, Kuo CS, Berger R, Nelson KR. Carbamazepinelnduced Cardiac Dysfunction: Characterization of Two Distinct Clinical Syndromes. Arch Intern Med. 1992;152(1):186-91.

15. Stone S, Lange LS. Syncope and sudden unexpected death attributed to carbamazepine in a 20-year-old epileptic. J Neurol Neurosurg Psychiatry. 1986;49(12):1460–1.

16. Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. DICP. 1990;24(12):1214-9.

17. Price R, Van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, ter Kuile F, Kham A, Chongsuphajaisiddhi T, White NJ, Nosten F. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg. 1999;60(4):547-55.

18. Butt TF, Branch RL, Beesley L, Martin U. Managing hypertension in the very elderly: effect of adverse drug reactions (ADRs) on achieving targets. J Hum Hypertens. 2010;24(8):514-8.

19. Dormán HR, Sondheimer JH, Cadnapaphornchai P. Mannitolinduced acute renal failure. Medicine. 1990;69(3):153-9.

20. Roberts B, Smith P. Hazards of mannitol infusions. The Lancet. 1966;288(2):421-2.

21. Warren SE, O'Connor DT. Hyperkalemia resulting from captopril administration. JAMA. 1980;244(22):2551-2.

22. Cambier C, Detry B, Beerens D, Florquin S, Ansay M, Frans A, Clerbaux T, Gustin P. Effects of hyperchloremia on blood oxygen binding in healthy calves. J App Physiol 1998;85(4):1267-72.

23. Martin WF, Armstrong LE, Rodriguez NR. Dietary protein intake and renal function. Nutr & Metab. 2005;2:25-9.